# At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)

> **NCT04270942** · PHASE2 · COMPLETED · sponsor: **Provention Bio, a Sanofi Company** · enrollment: 6 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** teplizumab 1 mg/mL

## Key facts

- **NCT ID:** NCT04270942
- **Lead sponsor:** Provention Bio, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-26
- **Primary completion:** 2024-01-22
- **Final completion:** 2024-01-22
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04270942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04270942, "At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT04270942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*